FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094998560> ?p ?o ?g. }

• W2094998560 endingPage "1471" @default.
• W2094998560 startingPage "1461" @default.
• W2094998560 abstract "Objective:Healthcare resource utilization in patients with multiple sclerosis (MS) is linked to relapses and disease progression. This retrospective cohort database analysis compared healthcare resource use and proxy measures of relapse outcomes in patients with active disease who switched to fingolimod or natalizumab.Methods:Using administrative claims data from the US PharMetrics Plus database, we identified patients with an MS diagnosis and a claim for fingolimod or natalizumab between 1 October 2010 and 30 June 2012 (index period) who had experienced a relapse (identified using a claims-based algorithm) and used other disease-modifying therapies (DMTs) in the previous year. Patients in the fingolimod and natalizumab cohorts were propensity score matched (1:1). MS-related inpatient stays, corticosteroid use and the proportion of patients experiencing claims-based relapses were assessed in the pre-index and post-index persistence periods. Time to first claims-based relapse in the post-index persistence period was assessed using a Kaplan–Meier curve.Results:The study included 623 unmatched patients (299 and 324 patients in the fingolimod and natalizumab cohorts, respectively) and 370 matched patients (185 in each cohort). In the matched analysis, MS-related inpatient stays and corticosteroid use were similar in the fingolimod and natalizumab cohorts during the post-index persistence period, and were significantly reduced versus the pre-index period (p < 0.01). A similar proportion of patients in the fingolimod and natalizumab cohorts were free from claims-based relapses in the persistence period (68.1% and 68.6%, respectively). There was no significant difference in the likelihood of experiencing a claims-based relapse (p = 0.8696).Limitation:Identification of relapses is based on database claims rather than on clinical assessment.Conclusions:In analyses of patients with MS with a history of relapse and DMT use, fingolimod and natalizumab reduce healthcare resource utilization and have similar effectiveness in a real-world setting." @default.
• W2094998560 created "2016-06-24" @default.
• W2094998560 creator A5002243119 @default.
• W2094998560 creator A5013496211 @default.
• W2094998560 creator A5029770183 @default.
• W2094998560 creator A5085553934 @default.
• W2094998560 date "2014-05-02" @default.
• W2094998560 modified "2023-10-16" @default.
• W2094998560 title "Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis" @default.
• W2094998560 cites W1512495229 @default.
• W2094998560 cites W2014094373 @default.
• W2094998560 cites W2017715038 @default.
• W2094998560 cites W2019582599 @default.
• W2094998560 cites W2028122031 @default.
• W2094998560 cites W2036193982 @default.
• W2094998560 cites W2054079814 @default.
• W2094998560 cites W2058555284 @default.
• W2094998560 cites W2059810353 @default.
• W2094998560 cites W2067338532 @default.
• W2094998560 cites W2101710086 @default.
• W2094998560 cites W2103758700 @default.
• W2094998560 cites W2104948944 @default.
• W2094998560 cites W2106769294 @default.
• W2094998560 cites W2127837073 @default.
• W2094998560 cites W2131902490 @default.
• W2094998560 cites W2132555717 @default.
• W2094998560 cites W2139367012 @default.
• W2094998560 cites W2148084100 @default.
• W2094998560 cites W2151340435 @default.
• W2094998560 cites W2171614089 @default.
• W2094998560 cites W2984556666 @default.
• W2094998560 cites W4292229870 @default.
• W2094998560 doi "https://doi.org/10.1185/03007995.2014.915802" @default.
• W2094998560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24754349" @default.
• W2094998560 hasPublicationYear "2014" @default.
• W2094998560 type Work @default.
• W2094998560 sameAs 2094998560 @default.
• W2094998560 citedByCount "27" @default.
• W2094998560 countsByYear W20949985602015 @default.
• W2094998560 countsByYear W20949985602016 @default.
• W2094998560 countsByYear W20949985602017 @default.
• W2094998560 countsByYear W20949985602018 @default.
• W2094998560 countsByYear W20949985602019 @default.
• W2094998560 countsByYear W20949985602020 @default.
• W2094998560 countsByYear W20949985602022 @default.
• W2094998560 crossrefType "journal-article" @default.
• W2094998560 hasAuthorship W2094998560A5002243119 @default.
• W2094998560 hasAuthorship W2094998560A5013496211 @default.
• W2094998560 hasAuthorship W2094998560A5029770183 @default.
• W2094998560 hasAuthorship W2094998560A5085553934 @default.
• W2094998560 hasConcept C126322002 @default.
• W2094998560 hasConcept C160735492 @default.
• W2094998560 hasConcept C162324750 @default.
• W2094998560 hasConcept C167135981 @default.
• W2094998560 hasConcept C17923572 @default.
• W2094998560 hasConcept C1862650 @default.
• W2094998560 hasConcept C201903717 @default.
• W2094998560 hasConcept C203014093 @default.
• W2094998560 hasConcept C2776036978 @default.
• W2094998560 hasConcept C2779134260 @default.
• W2094998560 hasConcept C2780640218 @default.
• W2094998560 hasConcept C2781004633 @default.
• W2094998560 hasConcept C41008148 @default.
• W2094998560 hasConcept C50522688 @default.
• W2094998560 hasConcept C71924100 @default.
• W2094998560 hasConcept C72563966 @default.
• W2094998560 hasConcept C77088390 @default.
• W2094998560 hasConceptScore W2094998560C126322002 @default.
• W2094998560 hasConceptScore W2094998560C160735492 @default.
• W2094998560 hasConceptScore W2094998560C162324750 @default.
• W2094998560 hasConceptScore W2094998560C167135981 @default.
• W2094998560 hasConceptScore W2094998560C17923572 @default.
• W2094998560 hasConceptScore W2094998560C1862650 @default.
• W2094998560 hasConceptScore W2094998560C201903717 @default.
• W2094998560 hasConceptScore W2094998560C203014093 @default.
• W2094998560 hasConceptScore W2094998560C2776036978 @default.
• W2094998560 hasConceptScore W2094998560C2779134260 @default.
• W2094998560 hasConceptScore W2094998560C2780640218 @default.
• W2094998560 hasConceptScore W2094998560C2781004633 @default.
• W2094998560 hasConceptScore W2094998560C41008148 @default.
• W2094998560 hasConceptScore W2094998560C50522688 @default.
• W2094998560 hasConceptScore W2094998560C71924100 @default.
• W2094998560 hasConceptScore W2094998560C72563966 @default.
• W2094998560 hasConceptScore W2094998560C77088390 @default.
• W2094998560 hasIssue "8" @default.
• W2094998560 hasLocation W20949985601 @default.
• W2094998560 hasLocation W20949985602 @default.
• W2094998560 hasOpenAccess W2094998560 @default.
• W2094998560 hasPrimaryLocation W20949985601 @default.
• W2094998560 hasRelatedWork W1972668457 @default.
• W2094998560 hasRelatedWork W1994801541 @default.
• W2094998560 hasRelatedWork W2053484098 @default.
• W2094998560 hasRelatedWork W2169569625 @default.
• W2094998560 hasRelatedWork W2338099154 @default.
• W2094998560 hasRelatedWork W2343984847 @default.
• W2094998560 hasRelatedWork W2588210285 @default.
• W2094998560 hasRelatedWork W2766897926 @default.
• W2094998560 hasRelatedWork W2977883158 @default.

• next